Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 6/2015

01-04-2015 | Review Article

Clinical Association Between Pharmacogenomics and Adverse Drug Reactions

Authors: Zhi-Wei Zhou, Xiao-Wu Chen, Kevin B. Sneed, Yin-Xue Yang, Xueji Zhang, Zhi-Xu He, Kevin Chow, Tianxin Yang, Wei Duan, Shu-Feng Zhou

Published in: Drugs | Issue 6/2015

Login to get access

Abstract

Adverse drug reactions (ADRs) are a major public health concern and cause significant patient morbidity and mortality. Pharmacogenomics is the study of how genetic polymorphisms affect an individual’s response to pharmacotherapy at the level of a whole genome. This article updates our knowledge on how genetic polymorphisms of important genes alter the risk of ADR occurrence after an extensive literature search. To date, at least 244 pharmacogenes identified have been associated with ADRs of 176 clinically used drugs based on PharmGKB. At least 28 genes associated with the risk of ADRs have been listed by the Food and Drug Administration as pharmacogenomic biomarkers. With the availability of affordable and reliable testing tools, pharmacogenomics looks promising to predict, reduce, and minimize ADRs in selected populations.
Literature
1.
2.
Bienfait KL, Shaw PM, Murthy G, Warner AW. Mobilizing pharmacogenomic analyses during clinical trials in drug development. Pharmacogenomics. 2013;14(10):1227–35.PubMedCrossRef
3.
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15–9.PubMedCentralPubMedCrossRef
4.
Morimoto T, Sakuma M, Matsui K, Kuramoto N, Toshiro J, Murakami J, et al. Incidence of adverse drug events and medication errors in Japan: the JADE study. J Gen Intern Med. 2011;26(2):148–53.PubMedCentralPubMedCrossRef
5.
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–5.PubMedCrossRef
6.
Evans WE, McLeod HL. Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538–49.PubMedCrossRef
7.
Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286(18):2270–9.PubMedCrossRef
8.
9.
Beutler E. The hemolytic effect of primaquine and related compounds: a review. Blood. 1959;14(2):103–39.PubMed
10.
Allderdice PW, Gardner HA, Galutira D, Lockridge O, LaDu BN, McAlpine PJ. The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26. Genomics. 1991;11(2):452–4.PubMedCrossRef
11.
Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2012;13(11):1285–306.PubMedCrossRef
12.
Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J. 2013;13(1):1–11.PubMedCrossRef
13.
International Transporter C, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36.CrossRef
14.
15.
van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics. 2001;11(4):287–91.PubMedCrossRef
16.
Twardowschy CA, Werneck LC, Scola RH, De Paola L, Silvado CE. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation. Arquivos de neuro-psiquiatria. 2011;69(2A):153–8.PubMed
17.
Samardzija M, Topic E, Stefanovic M, Zibar L, Samardzija G, Balen S, et al. Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy. Coll Antropol. 2008;32(2):557–64.PubMed
18.
Lee SY, Lee ST, Kim JW. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting. J Biochem Mol Biol. 2007;40(3):448–52.PubMedCrossRef
19.
Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004;141(2):205–8.PubMedCentralPubMedCrossRef
20.
21.
Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest. 2003;33(Suppl 2):23–30.PubMedCrossRef
22.
Giusti B, Gori AM, Marcucci R, Abbate R. Current status of clopidogrel pharmacogenomics. Pharmacogenomics. 2012;13(15):1671–4.PubMedCrossRef
23.
Yin T, Miyata T. Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res. 2011;128(4):307–16.PubMedCrossRef
24.
Thieme D, Rolf B, Sachs H, Schmid D. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int J Legal Med. 2008;122(2):149–55.PubMedCrossRef
25.
Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93(5):402–8.PubMedCentralPubMedCrossRef
26.
de Leon J. CYP2D6 genotyping and codeine. Paediatr Anaesth. 2008;18(3):274–5 (author reply 5–6).PubMedCrossRef
27.
Slanar O, Dupal P, Matouskova O, Vondrackova H, Pafko P, Perlik F. Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms. Bratislavske lekarske listy. 2012;113(3):152–5.PubMed
28.
Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci. 2007;96(9):2224–31.PubMedCrossRef
29.
Vinetti M, Haufroid V, Capron A, Classen JF, Marchandise S, Hantson P. Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms. Clin Toxicol. 2011;49(9):865–9.CrossRef
30.
Borobia AM, Novalbos J, Guerra-Lopez P, Lopez-Rodriguez R, Tabares B, Rodriguez V, et al. Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. Pharmacol Res. 2009;59(6):393–8.PubMedCrossRef
31.
Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol. 2010;160(4):919–30.PubMedCentralPubMedCrossRef
32.
Ueda M, Hirokane G, Morita S, Okawa M, Watanabe T, Akiyama K, et al. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):486–91.PubMedCrossRef
33.
Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem. 2005;51(2):376–85.PubMedCrossRef
34.
Yiannakopoulou E. Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications. Pharmacogenomics J. 2013;13(2):105–9.PubMedCrossRef
35.
Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008;112(9):1932–40.PubMedCrossRef
36.
Yang L, Price ET, Chang CW, Li Y, Huang Y, Guo LW, et al. Gene expression variability in human hepatic drug metabolizing enzymes and transporters. PloS one. 2013;8(4):e60368.PubMedCentralPubMedCrossRef
37.
Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet. 2006;15(5):797–805.PubMedCrossRef
38.
Mostafa-Hedeab G, Saber-Ayad MM, Latif IA, Elkashab SO, Elshaboney TH, Mostafa MI, et al. Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. J Clin Pharmacol. 2013;53(8):827–33.PubMedCrossRef
39.
Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18(10):1400–4.PubMedCrossRef
40.
Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci. 2001;22(6):298–305.PubMedCrossRef
41.
Mangravite LM, Wilke RA, Zhang J, Krauss RM. Pharmacogenomics of statin response. Curr Opin Mol Ther. 2008;10(6):555–61.PubMed
42.
Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007;6(11):904–16.PubMedCentralPubMedCrossRef
43.
Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med. 2008;359(8):789–99.CrossRef
44.
Stewart A. SLCO1B1 polymorphisms and statin-induced myopathy. PLoS Curr. 2013;5.
45.
Crist RC, Berrettini WH. Pharmacogenetics of OPRM1. Pharmacol Biochem Behav. 2014;123C:25–33.CrossRef
46.
Knapman A, Connor M. Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human mu-opioid receptor (OPRM1). Br J Pharmacol. 2015;172(2):349–63.PubMedCrossRef
47.
Walter C, Doehring A, Oertel BG, Lotsch J. μ-opioid receptor gene variant OPRM1 118 A>G: a summary of its molecular and clinical consequences for pain. Pharmacogenomics. 2013;14(15):1915–25.PubMedCrossRef
48.
Oertel BG, Kettner M, Scholich K, Renne C, Roskam B, Geisslinger G, et al. A common human μ-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem. 2009;284(10):6530–5.PubMedCrossRef
49.
Liang SQ, Chen XL, Deng JM, Wei X, Gong C, Chen ZR, et al. β2-adrenergic receptor (ADRB2) gene polymorphisms and the risk of asthma: a meta-analysis of case-control studies. PloS one. 2014;9(8):e104488.PubMedCentralPubMedCrossRef
50.
Al-Rubaish A. β2-adrenergic receptor gene polymorphisms in normal and asthmatic individuals in the Eastern Province of Saudi Arabia. Ann Saudi Med. 2011;31(6):586–90.PubMedCentralPubMedCrossRef
51.
Owen SA, Lunt M, Bowes J, Hider SL, Bruce IN, Thomson W, et al. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J. 2013;13(2):137–47.PubMedCrossRef
52.
53.
Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med. 2004;82(3):182–8.PubMedCrossRef
54.
Liu K, Yang T, Viswanathan PC, Roden DM. New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation. 2005;112(21):3239–46.PubMedCrossRef
55.
56.
Ramirez AH, Shaffer CM, Delaney JT, Sexton DP, Levy SE, Rieder MJ, et al. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J. 2013;13(4):325–9.PubMedCentralPubMedCrossRef
57.
Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105(16):1943–8.PubMedCrossRef
58.
Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci. 2000;97(19):10613–8.PubMedCentralPubMedCrossRef
59.
Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother. 1999;33(1):22–6.PubMedCrossRef
60.
Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation. 1997;96(9):2778–81.PubMedCrossRef
61.
62.
Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Ann Rev Pharmacol Toxicol. 2012;10(52):21–35.CrossRef
63.
Low SK, Takahashi A, Mushiroda T, Kubo M. Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. Clin Cancer Res. 2014;20(10):2541–52.PubMedCrossRef
64.
65.
McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, et al. HLA-A*31:01 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134–43.PubMedCentralPubMedCrossRef
66.
Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609–16.PubMedCentralPubMedCrossRef
67.
Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe’er I, Floratos A, et al. HLA-B*57:01 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816–9.PubMedCrossRef
68.
Shen Y, Nicoletti P, Floratos A, Pirmohamed M, Molokhia M, Geppetti P, et al. Genome-wide association study of serious blistering skin rash caused by drugs. Pharmacogenomics J. 2012;12(2):96–104.PubMedCrossRef
69.
Sadee W, Wang D, Papp AC, Pinsonneault JK, Smith RM, Moyer RA, et al. Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin Pharmacol Ther. 2011;89(3):355–65.PubMedCentralPubMedCrossRef
70.
Hartford C, Yang W, Cheng C, Fan Y, Liu W, Trevino L, et al. Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia. 2007;21(10):2128–36.PubMedCrossRef
71.
Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the γ-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics. 2008;18(4):317–23.PubMedCrossRef
72.
Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8(3):186–95.PubMedCrossRef
73.
Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008;112(7):2709–12.PubMedCrossRef
74.
Volpi S, Heaton C, Mack K, Hamilton JB, Lannan R, Wolfgang CD, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry. 2009;14(11):1024–31.PubMedCrossRef
75.
Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009;27(35):5972–8.PubMedCentralPubMedCrossRef
76.
Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464(7287):405–8.PubMedCrossRef
77.
Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42(8):711–4.PubMedCrossRef
78.
Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20(5):1034–41.PubMedCrossRef
79.
Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141(1):338–47.PubMedCentralPubMedCrossRef
80.
Kaab S, Crawford DC, Sinner MF, Behr ER, Kannankeril PJ, Wilde AA, et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet. 2012;5(1):91–9.PubMedCentralPubMedCrossRef
81.
Kurose K, Hiratsuka K, Ishiwata K, Nishikawa J, Nonen S, Azuma J, et al. Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry Res. 2012;198(3):424–9.PubMedCrossRef
82.
Kiyotani K, Uno S, Mushiroda T, Takahashi A, Kubo M, Mitsuhata N, et al. A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet Genomics. 2012;22(4):229–35.PubMedCrossRef
83.
Behr ER, Ritchie MD, Tanaka T, Kaab S, Crawford DC, Nicoletti P, et al. Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. PloS one. 2013;8(11):e78511.PubMedCentralPubMedCrossRef
84.
Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, et al. A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 2013;13(1):60–9.PubMedCrossRef
85.
Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012;39(7):594–601.PubMedCrossRef
86.
Chung S, Low SK, Zembutsu H, Takahashi A, Kubo M, Sasa M, et al. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients. Breast Cancer Res. 2013;15(5):R81.PubMedCentralPubMedCrossRef
87.
Fernandez-Rozadilla C, Cazier JB, Moreno V, Crous-Bou M, Guino E, Duran G, et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J. 2013;13(3):209–17.PubMedCrossRef
88.
Leandro-Garcia LJ, Inglada-Perez L, Pita G, Hjerpe E, Leskela S, Jara C, et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet. 2013;50(9):599–605.PubMedCrossRef
89.
Zabala W, Cruz R, Barreiro-de Acosta M, Chaparro M, Panes J, Echarri A, et al. New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients. Pharmacogenomics. 2013;14(6):631–40.PubMedCrossRef
90.
Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013;121(6):898–904.PubMedCentralPubMedCrossRef
91.
Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, et al. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013;19(2):491–9.PubMedCentralPubMedCrossRef
92.
Park BL, Kim TH, Kim JH, Bae JS, Pasaje CF, Cheong HS, et al. Genome-wide association study of aspirin-exacerbated respiratory disease in a Korean population. Hum Genet. 2013;132(3):313–21.PubMedCrossRef
93.
Zhang FR, Liu H, Irwanto A, Fu XA, Li Y, Yu GQ, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 2013;369(17):1620–8.PubMedCrossRef
94.
Cornejo-Garcia JA, Liou LB, Blanca-Lopez N, Dona I, Chen CH, Chou YC, et al. Genome-wide association study in NSAID-induced acute urticaria/angioedema in Spanish and Han Chinese populations. Pharmacogenomics. 2013;14(15):1857–69.PubMedCrossRef
95.
Wheeler HE, Gonzalez-Neira A, Pita G, de la Torre-Montero JC, Alonso R, Lopez-Fernandez LA, et al. Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. Pharmacogenet Genomics. 2014;24(5):231–7.PubMed
96.
Chung WH, Chang WC, Lee YS, Wu YY, Yang CH, Ho HC, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014;312(5):525–34.PubMedCrossRef
Metadata
Title
Clinical Association Between Pharmacogenomics and Adverse Drug Reactions
Authors
Zhi-Wei Zhou
Xiao-Wu Chen
Kevin B. Sneed
Yin-Xue Yang
Xueji Zhang
Zhi-Xu He
Kevin Chow
Tianxin Yang
Wei Duan
Shu-Feng Zhou
Publication date
01-04-2015
Publisher
Springer International Publishing
Published in
Drugs / Issue 6/2015
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-015-0375-0

Other articles of this Issue 6/2015

Drugs 6/2015 Go to the issue

Adis Drug Evaluation

Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C

Review Article

Depression in Type 2 Diabetes Mellitus: Prevalence, Impact, and Treatment

Adis Drug Evaluation

Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Adis Drug Evaluation

Olodaterol: A Review of Its Use in Chronic Obstructive Pulmonary Disease

Leading Article

The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date

R&D Insight Report

Finafloxacin: First Global Approval